Literature DB >> 24291939

[Management of chronic migraine in Japan].

Yuka Watanabe1, Ryotaro Takashima, Hisatake Iwanami, Shiho Suzuki, Hisaka Igarashi, Koichi Hirata.   

Abstract

The Japanese Headache Society and the Japanese Society of Neurology has published the 2013 guidelines for the diagnosis and treatment of chronic headache. A new CQ has been set up in the guidelines on the topic of "How to treat chronic migraine." In the past, lomerizine was the only prophylactic medication of migraine that was eligible under insurance coverage. However, afterward in 2010, valproate was added to the list of antimigraine medications approved under insurance coverage, followed by propranolol, amitriptyline, and verapamil, with rapid advances in the treatment of migraine. Valproate, topiramate (not approved under insurance coverage until date), and amitriptyline could potentially be used in the treatment of chronic migraine in Japan; further, considering the clinical outcomes thus far, lomerizine could also be added to the list. As a drug for migraine prophylaxis, valproate is contraindicated in pregnant women and needs to be used with caution.

Entities:  

Mesh:

Year:  2013        PMID: 24291939     DOI: 10.5692/clinicalneurol.53.1228

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  2 in total

1.  A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.

Authors:  Fumihiko Sakai; Takao Takeshima; Yoshihisa Tatsuoka; Koichi Hirata; Robert Lenz; Yi Wang; Sunfa Cheng; Toshiyasu Hirama; Daniel D Mikol
Journal:  Headache       Date:  2019-10-14       Impact factor: 5.887

2.  Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial.

Authors:  Koichi Hirata; Fumihiko Sakai; Takao Takeshima; Noboru Imai; Yasuhiko Matsumori; Ryuji Yoshida; Yotaro Numachi; Cheng Peng; Daniel D Mikol; Sunfa Cheng
Journal:  J Headache Pain       Date:  2021-09-18       Impact factor: 7.277

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.